Maker Novo Nordisk is retiring a range of formulations between now and the end of 2026.
Danish pharmaceutical giant Novo Nordisk, maker of semaglutide blockbusters Ozempic and Wegovy, has announced to the TGA it will discontinue a range of insulin products over the next two years.
In some cases only one format or “presentation” of a product is being withdrawn.
The presentations and their expected end dates are:
- Mixtard 30 Penfill (insulin human/isophane (NPH) insulin human 30/70), October 2024
- Fiasp vials (fast acting insulin aspart), December 2024
- Ryzodeg FlexTouch (insulin degludec + insulin aspart 70/30), February 2025
- Protaphane InnoLet (isophane (NPH) insulin human), February 2025
- Fiasp FlexTouch (fast acting insulin aspart), June 2025
- Protaphane Penfill (isophane (NPH) insulin human), December 2026
- Levemir FlexPen & Penfill (insulin detemir), December 2026
- Actrapid Penfill (human insulin), December 2026
- NovoFine Autocover December 2026
Ryzodeg FlexTouch has been in shortage this year as a result of “unprecedented” global demand for the delivery device.
The TGA has undertaken to “work with the sponsor to minimise the impact of these discontinuations by providing early advice that includes alternative options”.
